Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Asthma affects over 260 million people globally, with significant health impacts. The Global Initiative for Asthma (GINA) 2024 report recommends inhaled corticosteroid/long-acting β-agonist (ICS/LABA) combinations, including fluticasone propionate/salmeterol (FP/SAL) and budesonide/formoterol (BUD/FOR), for maintenance treatment. Both combinations have demonstrated clinical benefits, with previous clinical trials and real-world studies showing comparable asthma control with FP/SAL and BUD/FOR. This United States (US)-based study compares the real-world effectiveness of FP/SAL and BUD/FOR on asthma control and treatment adherence.
Methods: This retrospective cohort study analyzed data from the US Optum's Market Clarity database (July 1, 2010, to December 31, 2019), with integrated medical, pharmacy claims, and clinical electronic health records. Patients aged ≥18 years with asthma at GINA Steps 3-4, and ≥1 pharmacy claim for FP/SAL or BUD/FOR (index) were included. Patients on other ICS/LABA therapy ≥12 months prior to index were excluded. Inverse probability of treatment weighting adjusted for confounders. Outcomes were stratified by asthma severity.
Results: A total of 57,000 patients were included (FP/SAL: 28,639; BUD/FOR: 28,361). Baseline characteristics were balanced post-weighting. Asthma control was similar between cohorts, with no significant differences in Asthma Control Test scores or short-acting β-agonist fills during the 12-month period following the index. Treatment adherence, assessed using proportion of days covered (≥0.8), was higher in the FP/SAL cohort (5.4 %) versus the BUD/FOR cohort (4.4 %; p < 0.001).
Conclusions: FP/SAL and BUD/FOR were similarly effective for asthma control in real-world settings, while FP/SAL was generally associated with greater medication adherence, a key factor for long-term control.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.rmed.2025.108172 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
S-nitrosylation of pVHL regulates β adrenergic receptor function.
Proc Natl Acad Sci U S A
September 2025
Department of Medicine, Institute for Transformative Molecular Medicine, Case Western Reserve University School of Medicine, Cleveland, OH 44106.
The β-adrenergic receptor (βAR), a prototype G protein-coupled receptor, controls cardiopulmonary function underpinning O delivery. Abundance of the βAR is canonically regulated by G protein-coupled receptor kinases and β-arrestins, but neither controls constitutive receptor levels, which are dependent on ambient O. Basal βAR expression is instead regulated by the prolyl hydroxylase/pVHL-E3 ubiquitin ligase system, explaining O responsivity.
View Article and Find Full Text PDFObservational Study: Lung Function and Symptom Control in Youth With Asthma up to 34 Months After COVID-19.
Pediatr Pulmonol
September 2025
Department of Pediatrics, Division of Pulmonology, Indiana University of School of Medicine, Indianapolis, Indiana, USA.
Introduction: Prior studies of pediatric asthma control and lung function after COVID-19 have been limited by short follow-up intervals. We aimed to evaluate symptom control and lung function in children with asthma up to 34 months post-COVID-19.
Methods: We conducted a prospective observational chart review study.
The Association Between Use of Inhaled Corticosteroids and Long-Acting Beta2-Agonists During Pregnancy and Adverse Fetal Outcomes.
Respirology
September 2025
Department of Pharmacy, College of Pharmaceutical Sciences, National Yang, Ming Chiao Tung University, Taipei, Taiwan.
Background And Objective: Women with asthma should continue controller therapy during pregnancy, but current evidence on the effects of inhaled corticosteroids (ICS) and long-acting beta2-agonists (LABA) on adverse fetal outcomes remains unclear.
Methods: This was a population-based retrospective cohort study. Data were derived from the Health and Welfare Database, Birth Certificate Application, and Maternal and Child Health Database in Taiwan, from January 1, 2007 to December 31, 2018.
Efficacy of hypertonic saline nasal irrigation in allergic rhinitis: A systematic review and meta-analysis.
Allergol Immunopathol (Madr)
September 2025
Department of Pulmonary Medicine, Rajasthan Hospital, Jaipur, India.
Saline nasal irrigation provides symptom relief in allergic rhinitis (AR), but the optimal saline concentration remains uncertain. The comparative efficacy of 3% hypertonic saline nasal irrigation (HSNI) versus 0.9% isotonic saline is still debated.
View Article and Find Full Text PDFAssociation between serum copper and childhood asthma: A systematic review and meta-analysis.
Allergol Immunopathol (Madr)
September 2025
Department of Respiratory Disease, Children's Hospital Affiliated to Shandong University, Jinan, China.
Background: Asthma is a chronic respiratory disease with complex pathogenesis. Some studies suggest that certain trace metals may be associated with asthma. However, the relationship between serum copper (Cu) and childhood asthma remains unclear.
View Article and Find Full Text PDF